Science in the Age of Experience 2024 - Willem van Hoorn

Experience in the age of AI

After working for ten years at Pfizer as a computational chemist specializing in chemoinformatics, Willem van Hoorn joined an AI-powered drug discovery company. Now an independent consultant, he joined "Science In The Age Of Experience 2024 - Generative Sciences for Society" to share his insights on how AI can accelerate drug discovery, why it hasn’t been as fast as we hoped, and what it takes to get back on track:

​​​​​​​The first wave of companies that pioneered the use AI in drug discovery were founded around 2010, claiming to dramatically speed up the rate of drug discovery. More than a decade has now passed, so where are the promised drug candidates? 

A quick glance on your favourite social network feed will include multiple headlines decrying the failure of AI in drug discovery. I was cofounder of one of these companies and spent more than a decade there. Was it all hype and were my efforts in vain or is this a case of unrealistic expectations that were never going to be fulfilled? I argue the latter, reports of the death of AI in drug discovery are greatly exaggerated.

🔔Don’t forget to subscribe:    / @dassaultsystemes  
🔔Dassault Systèmes official website: https://www.3ds.com/
🔔Learn more about what Dassault Systèmes do: https://www.3ds.com/about/company/wha...

🤳 Follow us! 🤳
Linkedin:   / dassaultsystemes  
TikTok:   / dassaultsystemes  
Instagram:   / dassaultsystemes  
Twitter:   / dassault3ds  
Facebook:   / dassaultsystemes  

#DassaultSystèmes #ScienceWeek #SAOE #3DS #3DEXPERIENCE